Episodic infliximab treatment induces infusion reactions.
Margo
F
F
Marques
M
M
Santos
C Costa
CC
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D012074:Remission Induction / Q000379:methods; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D000069285:Infliximab